Kaskela Law Investigates FONAR Buyout for Potential Undervaluation
Event summary
- Kaskela Law LLC is investigating FONAR Corp.'s proposed buyout at $19.00 per share in cash, announced on December 29, 2025.
- The investigation aims to determine if the buyout price undervalues FONAR's shares and whether company officers/directors breached fiduciary duties.
- FONAR shareholders will be cashed out, and the company's shares will no longer be publicly traded post-transaction.
The big picture
The investigation highlights the ongoing tension between shareholders and management in M&A deals, particularly in the healthcare sector where valuations can be contentious. It also underscores the role of investor protection firms in scrutinizing transactions for potential undervaluation and governance issues. The outcome could set a precedent for similar cases in the medical technology industry.
What we're watching
- Valuation Dispute
- Whether the $19.00 per share offer adequately reflects FONAR's true market value and growth potential.
- Legal Scrutiny
- The pace at which Kaskela Law's investigation progresses and potential legal actions that may arise.
- Shareholder Reaction
- How FONAR shareholders respond to the investigation and whether it impacts the transaction's approval.
Related topics